Lingyun Xiang Was Awarded the RSSG Royal Medal of Honor by the Royal Society of St. George
Lingyun Xiang was Awarded the RSSG Royal Medal of Honor by the Royal Society of St. George
The Royal Society of St. George, founded in 1894, is dedicated to promoting English culture, traditions, and patriotic spirit. Since its establishment, the society has enjoyed the support of the British monarchy, and its current patron is King Charles III.
Each year, the RSSG honors individuals who have made outstanding contributions in various fields at its annual gala.
Marquess Lingyun Xiang holds the title of Marquess of San Prospero, conferred upon him by the Austrian Royal Family and the Holy Roman Empire.
An economist living in the United States, Professor Lingyun Xiang holds certified public accountant qualifications in multiple countries. He is a recipient of the King's Medal of the United Kingdom and the European Excellence Award, a Fellow of the Royal Society of St. George, a Lifetime Fellow of the Royal Society of Arts, and a Foreign Academician of the National Academy of Engineering of Ukraine.
He serves as a Lifetime Professor at the European University, a doctoral Advisor at the University of Maryland, a distinguished Professor at Peking University, and a Visiting Professor at Beijing Union University, Capital Normal University, and Shaanxi University of Science and Technology.
He was previously honored with the title of "International Charity Ambassador".
He has served as an economic advisor to numerous countries and royal families, including the Royal Family of Thailand, the Republic of Chile, Ukraine, Turkey, Uzbekistan, the Plurinational State of Bolivia, Bosnia and Herzegovina, the Central African Republic, Haiti, Liberia, Libya, Zimbabwe, Madagascar, North Macedonia, Ghana, Gabon, Benin, Burundi, Côte d'Ivoire, Nigeria, Guinea-Bissau, and Mali, among others.
Contact：The Royal Society of St. GeorgeTel: +44 (0) 20 3225 5011Eml: info@rssg.org.uk
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252306
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Trump threatens 250pc tariffs on drug imports
Donald Trump has threatened to impose tariffs of up to 250pc on pharmaceutical imports in a major threat to one of Britain's key sectors. The US president, who has already warned global drugmakers to lower their domestic prices in the US, said he would be announcing tariffs for the industry 'within the next week or so'. Such a move could be damaging for the UK, which counts pharma giants AstraZeneca and GSK as two of its largest companies and employs 73,000 people in the sector overall. Britain has signed a trade agreement with the US but the pharmaceutical tariffs are expected to be outside the scope of the agreement, increasing the risk. 'We'll be putting an initially small tariff on pharmaceuticals but in one year, one and a half years maximum it's going to go to 150pc and then it's going to go to 250pc,' Mr Trump said in a US television interview on Tuesday. The president added that he would impose tariffs on pharmaceutical imports to the US 'because we want pharmaceuticals made in our country'. It marks a fresh threat to the industry, which is awaiting the outcome of an investigation by the US commerce department into the impact of imports on American national security. The US president said the tariffs on pharmaceutical imports would be 'a separate class' to a string of tariff deals announced in recent weeks, adding: 'These are excluded class, as I call them ... like steel, aluminium, etc.' Mr Trump has repeatedly made threats to impose various levels of tariffs on the industry before changing course. His latest comments on trade levies come just days before his latest tariff deadline on goods entering the US comes into effect on Aug 7. The president was also critical of India after the country's foreign ministry accused the US and the EU of double standards on buying Russian oil. The US is due to impose 25pc tariffs on imports from India but Trump threatened to lift this further in his latest escalation. 'We settled on 25pc but I think I'm going to raise that very substantially over the next 24 hours because they are buying Russian oil, they are fuelling the war machine, and if they're going do that I'm not going to be happy,' he said, adding that India had 'not been a good trading partner'. 'The sticking point with India is that tariffs are too high ... They will give us zero tariffs and they're going to let us go in but that's not good enough because of what they are doing with oil.' Mr Trump also renewed his attacks on Jerome Powell, the chairman of the Federal Reserve, and repeated his calls for the central bank to cut interest rates. 'Jay Powell is highly political and I call him ... Too Late Jerome, Too Late Powell,' he said. Mr Trump added that Scott Bessent, the US treasury secretary, 'does not want' to be chairman of the Federal Reserve but said that there were four others in the running for the position. Mr Powell's term as chairman of the Federal Reserve ends in May 2026. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
ReGen III Appoints Accomplished Executive as Chief Financial Officer to Drive Next Phase of Growth
Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - ReGen III Corp. (TSXV: GIII) (OTCQB: ISRJF) (FSE: PN4) ("ReGen III" or the "Company"), a leading clean technology company specializing in the upcycling of used motor oil ("UMO") into high-value Group III base oils, is pleased to announce the appointment of Brad Kotush as Chief Financial Officer. Mr. Kotush brings over 17 years' experience as a public company CFO with proven success in capital markets, corporate scaling, mergers and acquisitions ("M&A"), and public reporting. Mr. Kotush was most recently EVP and CFO for Home Capital Group Inc. ("Home") from 2017 to 2024. As a key member of Home's leadership team, Mr. Kotush helped drive share price appreciation of approximately 3.4 times, a $600 million expansion in market capitalization, and the return of more than $1.5 billion to shareholders through dividends and share repurchases. In addition, he served as due diligence team lead during Home's $1.7 billion privatization, which closed in August 2023. From 2006 to 2017, Mr. Kotush served as Executive Vice President, Chief Financial Officer, and Chief Risk Officer of Canaccord Genuity Group Inc., where he played a pivotal role in executing more than $750 million in domestic and international acquisitions and expanding the company's presence from two to ten countries. He also oversaw the company's dual listing on the UK's AIM exchange and subsequent transition to the London Stock Exchange. Throughout his career, Mr. Kotush has managed public and internal financial reporting, budgeting, risk management, regulatory reporting, treasury, investor relations, legal affairs, technology strategy, and operations across multiple senior roles in Canada, UK, and other jurisdictions. Mr. Kotush is a Chartered Professional Accountant (CPA, CA) and holds the ICD.D designation from the Institute of Corporate Directors. Quote from CEO & President, Tony Weatherill "We are beyond thrilled to welcome Brad Kotush as our Chief Financial Officer," said Tony Weatherill, CEO & President of ReGen III. "Brad's deep institutional knowledge, broad global capital markets expertise, and proven track record of strategically scaling companies make him an ideal fit for ReGen III. Brad has successfully guided organizations through transformational growth, completing and integrating strategic acquisitions that unlocked long-term value. His leadership will be instrumental as we position ReGen III for our next leg of growth." Quote from CFO, Brad Kotush "I am excited to join ReGen III at such a pivotal point," said Brad Kotush, Chief Financial Officer. "The Company's commitment to sustainable innovation and its ambitious growth plans resonate with me and I look forward to leveraging my extensive experience in capital markets, mergers and acquisitions, and organizational scale up to help drive ReGen III's next phase of growth and deliver long-term value for our shareholders." Options The Company has granted Mr. Kotush 1 million stock options at an exercise price of $0.19 per option, valid for five years from the date of grant. The options will vest over a period of four (4) years and may be accelerated by attaining specific performance milestones set by the Board of Directors. Attachments Brad Kotush, CPA, CA, ICD.D, Chief Financial Officer, ReGen III Corp. To view an enhanced version of this graphic, please visit: Leadership Transition Effective August 5, 2025, Rick Low has stepped down as Chief Financial Officer. To ensure a smooth transition, Rick will remain available in an advisory capacity for up to six months to support the handover of responsibilities. The Company wishes to thank Mr. Low for his steadfast leadership and many contributions throughout his tenure. In addition, Mark Redcliffe will be stepping away as EVP and Chief Strategy Officer. Mr. Redcliffe will continue to support ReGen III in a consulting capacity. Throughout his tenure with ReGen III, Mark has been pivotal in advancing ReGen III's mission, driving patent development, fostering offtake and feedstock agreements, and leading financing efforts. "Mark's strategic leadership has positioned us for success in sustainable base oil production," said Tony Weatherill. "We extend our heartfelt thanks to Mark for his extensive contributions, unwavering commitment, and ongoing guidance as a consultant." About ReGen III ReGen III Corp. is driving a new era in high-performance, sustainable lubricants. Harnessing its patented ReGen™ technology, the Company is commercializing an advanced process to transform used motor oil ("UMO") into premium Group II and III base oils. These high-quality base oils are essential to high-performance engines, turbines, and industrial applications — and ReGen III's process is designed to deliver up to 82% lower CO₂e emissions than virgin crude-derived oils combusted at end of life. By turning waste into high-value products, ReGen III is driving the shift toward circular, domestically-produced base oils that meet the growing global demand for sustainable Group III solutions. With FEL2 and value engineering complete for its proposed 5,600 bpd flagship facility in Texas City, Texas — and backed by world-class engineering, construction, and vendor partners — the Company is strategically positioned to meet rising demand for higher-quality, circular base oils. In addition to Texas City, the Company is evaluating opportunities to deploy its patented technology across other strategic markets. With the vision of becoming the world's largest producer of sustainable, re-refined Group III base oils, ReGen III aims to set a new standard for performance and responsibility in the global lubricants market. For more information on ReGen III or to subscribe to the Company's mailing list, please visit: and For further information, please contact: Investor & Media inquiries: Email: investors@ Corporate Inquiries: Kimberly Hedlin Vice President, Corporate Finance Tel: (403) 921-9012 Email: info@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain information other than statements of historical facts contained in this news release constitutes "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information"). Without limiting the foregoing, such forward-looking information includes statements regarding the Company's business plans, expectations, capital costs and objectives. In this news release, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking information. Forward looking information should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking information is based on information available at the time and/or the Company management's good faith belief with respect to future events and is subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. For additional information with respect to these and other factors and assumptions underlying the forward-looking information made in this news release, see the Company's most recent Management's Discussion and Analysis and financial statements and other documents filed by the Company with the Canadian securities commissions and the discussion of risk factors set out therein. Such documents are available at under the Company's profile and on the Company's website, The forward-looking information set forth herein reflects the Company's expectations as at the date of this news release and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. To view the source version of this press release, please visit
Yahoo
3 hours ago
- Yahoo
Medexus Schedules First Fiscal Quarter 2026 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, August 13, 2025 to discuss Medexus's results for its first fiscal quarter ended June 30, 2025. Medexus expects to file its financial statements and MD&A after markets close on August 12, 2025. To participate in the call, please dial the following numbers: 888-506-0062 (toll-free) for Canadian and U.S. callers+1 973-528-0011 for international callers Access code: 284388 A live webcast of the call will be available on the Investors section of Medexus's corporate website or at the following link: A replay of the call will be available approximately one hour following the end of the call through Wednesday, August 20, 2025. To access the replay, please dial the following numbers — 877-481-4010 for Canadian and U.S. callers+1 919-882-2331 for international callers Conference ID: 52801 A replay of the webcast will be available on the Investors section of Medexus's corporate website until Thursday, August 13, 2026. Company management will be available to discuss the company's commercialization activities at Cannacord Genuity's 45th Annual Growth Conference in Boston from August 12 to 14, 2025 and the LD Micro Main Event in San Diego from October 19 to 21, 2025. Details regarding Medexus's participation will be available on the Investors-News & Events section of Medexus's corporate website. About Medexus Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and allergy, dermatology, and rheumatology. For more information about Medexus and its product portfolio, please see the company's corporate website at and its filings on SEDAR+ at Contacts Ken d'Entremont | CEO, Medexus PharmaceuticalsTel: 905-676-0003 | Email: Brendon Buschman | CFO, Medexus PharmaceuticalsTel: 416-577-6216 | Email: Forward-looking statements Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
